IL273477B2 - Delivery pharmaceutical compositions including permeation enhancers - Google Patents
Delivery pharmaceutical compositions including permeation enhancersInfo
- Publication number
- IL273477B2 IL273477B2 IL273477A IL27347720A IL273477B2 IL 273477 B2 IL273477 B2 IL 273477B2 IL 273477 A IL273477 A IL 273477A IL 27347720 A IL27347720 A IL 27347720A IL 273477 B2 IL273477 B2 IL 273477B2
- Authority
- IL
- Israel
- Prior art keywords
- pharmaceutical composition
- composition according
- surfactant
- permeation enhancer
- polymeric matrix
- Prior art date
Links
- 239000003623 enhancer Substances 0.000 title 1
- 230000035515 penetration Effects 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 46
- 239000003961 penetration enhancing agent Substances 0.000 claims 17
- 239000004094 surface-active agent Substances 0.000 claims 17
- 239000003795 chemical substances by application Substances 0.000 claims 10
- 239000011159 matrix material Substances 0.000 claims 10
- -1 glycine betaine ester Chemical class 0.000 claims 8
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 claims 7
- 108010016076 Octreotide Proteins 0.000 claims 7
- 229960002700 octreotide Drugs 0.000 claims 7
- 230000001225 therapeutic effect Effects 0.000 claims 7
- XJWSAJYUBXQQDR-UHFFFAOYSA-M dodecyltrimethylammonium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)C XJWSAJYUBXQQDR-UHFFFAOYSA-M 0.000 claims 6
- 125000005842 heteroatom Chemical group 0.000 claims 6
- 229960003237 betaine Drugs 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 4
- 125000000304 alkynyl group Chemical group 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims 3
- 229920001577 copolymer Polymers 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 239000012528 membrane Substances 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 229920000858 Cyclodextrin Polymers 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 2
- 235000010489 acacia gum Nutrition 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000004450 alkenylene group Chemical group 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 239000004202 carbamide Substances 0.000 claims 2
- 235000013877 carbamide Nutrition 0.000 claims 2
- 239000002738 chelating agent Substances 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 125000002993 cycloalkylene group Chemical group 0.000 claims 2
- 230000003413 degradative effect Effects 0.000 claims 2
- 230000002209 hydrophobic effect Effects 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 239000000693 micelle Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 1
- 125000000923 (C1-C30) alkyl group Chemical group 0.000 claims 1
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims 1
- WDJHALXBUFZDSR-UHFFFAOYSA-N Acetoacetic acid Natural products CC(=O)CC(O)=O WDJHALXBUFZDSR-UHFFFAOYSA-N 0.000 claims 1
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims 1
- 229920002101 Chitin Polymers 0.000 claims 1
- 229920001661 Chitosan Polymers 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- 102000008186 Collagen Human genes 0.000 claims 1
- 108010035532 Collagen Proteins 0.000 claims 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 108010010803 Gelatin Proteins 0.000 claims 1
- 229920002907 Guar gum Polymers 0.000 claims 1
- 229920000084 Gum arabic Polymers 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 1
- 239000004373 Pullulan Substances 0.000 claims 1
- 229920001218 Pullulan Polymers 0.000 claims 1
- 229920002125 Sokalan® Polymers 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 239000000205 acacia gum Substances 0.000 claims 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 claims 1
- 150000001241 acetals Chemical class 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 238000004220 aggregation Methods 0.000 claims 1
- 230000002776 aggregation Effects 0.000 claims 1
- 125000004419 alkynylene group Chemical group 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 125000000129 anionic group Chemical group 0.000 claims 1
- 239000003945 anionic surfactant Substances 0.000 claims 1
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 claims 1
- 229960000686 benzalkonium chloride Drugs 0.000 claims 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims 1
- 239000003833 bile salt Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims 1
- 239000003093 cationic surfactant Substances 0.000 claims 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 claims 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 230000002867 ciliostatic effect Effects 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 229920001436 collagen Polymers 0.000 claims 1
- 239000000412 dendrimer Substances 0.000 claims 1
- 229920000736 dendritic polymer Polymers 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- WOWBFOBYOAGEEA-UHFFFAOYSA-N diafenthiuron Chemical compound CC(C)C1=C(NC(=S)NC(C)(C)C)C(C(C)C)=CC(OC=2C=CC=CC=2)=C1 WOWBFOBYOAGEEA-UHFFFAOYSA-N 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 150000002081 enamines Chemical class 0.000 claims 1
- 238000006911 enzymatic reaction Methods 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 230000004136 fatty acid synthesis Effects 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 229920000159 gelatin Polymers 0.000 claims 1
- 239000008273 gelatin Substances 0.000 claims 1
- 235000019322 gelatine Nutrition 0.000 claims 1
- 235000011852 gelatine desserts Nutrition 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 229930182470 glycoside Natural products 0.000 claims 1
- 239000000665 guar gum Substances 0.000 claims 1
- 235000010417 guar gum Nutrition 0.000 claims 1
- 229960002154 guar gum Drugs 0.000 claims 1
- 229920000591 gum Polymers 0.000 claims 1
- 150000002373 hemiacetals Chemical class 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims 1
- 230000007062 hydrolysis Effects 0.000 claims 1
- 238000006460 hydrolysis reaction Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims 1
- 229920000587 hyperbranched polymer Polymers 0.000 claims 1
- 150000002500 ions Chemical class 0.000 claims 1
- 239000012948 isocyanate Substances 0.000 claims 1
- 150000002513 isocyanates Chemical class 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 150000004667 medium chain fatty acids Chemical class 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000003232 mucoadhesive effect Effects 0.000 claims 1
- 230000000510 mucolytic effect Effects 0.000 claims 1
- 210000003097 mucus Anatomy 0.000 claims 1
- 239000002840 nitric oxide donor Substances 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 239000002736 nonionic surfactant Substances 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 150000002905 orthoesters Chemical class 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims 1
- 125000005496 phosphonium group Chemical group 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 230000035479 physiological effects, processes and functions Effects 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 229920002627 poly(phosphazenes) Polymers 0.000 claims 1
- 239000004584 polyacrylic acid Substances 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 235000019423 pullulan Nutrition 0.000 claims 1
- 125000001453 quaternary ammonium group Chemical group 0.000 claims 1
- 150000003872 salicylic acid derivatives Chemical class 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 235000010413 sodium alginate Nutrition 0.000 claims 1
- 239000000661 sodium alginate Substances 0.000 claims 1
- 229940005550 sodium alginate Drugs 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 230000006641 stabilisation Effects 0.000 claims 1
- 238000011105 stabilization Methods 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 150000007970 thio esters Chemical class 0.000 claims 1
- 239000003071 vasodilator agent Substances 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- 239000000230 xanthan gum Substances 0.000 claims 1
- 229920001285 xanthan gum Polymers 0.000 claims 1
- 235000010493 xanthan gum Nutrition 0.000 claims 1
- 229940082509 xanthan gum Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762563534P | 2017-09-26 | 2017-09-26 | |
| PCT/US2018/052927 WO2019067596A1 (en) | 2017-09-26 | 2018-09-26 | ADMINISTRATIVE PHARMACEUTICAL COMPOSITIONS CONTAINING PERMEATION PROMOTERS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL273477A IL273477A (en) | 2020-05-31 |
| IL273477B1 IL273477B1 (en) | 2024-04-01 |
| IL273477B2 true IL273477B2 (en) | 2024-08-01 |
Family
ID=63858155
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL273477A IL273477B2 (en) | 2017-09-26 | 2018-09-26 | Delivery pharmaceutical compositions including permeation enhancers |
| IL311142A IL311142A (en) | 2017-09-26 | 2018-09-26 | Delivery pharmaceutical compositions including permeation enhancers |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL311142A IL311142A (en) | 2017-09-26 | 2018-09-26 | Delivery pharmaceutical compositions including permeation enhancers |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20190091281A1 (https=) |
| EP (1) | EP3687508A1 (https=) |
| JP (2) | JP2020535232A (https=) |
| KR (1) | KR20200059269A (https=) |
| CN (1) | CN111148512A (https=) |
| BR (1) | BR112020005875A2 (https=) |
| CA (1) | CA3076751A1 (https=) |
| IL (2) | IL273477B2 (https=) |
| WO (1) | WO2019067596A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL313551A (en) * | 2017-09-27 | 2024-08-01 | Aquestive Therapeutics Inc | Enhanced delivery epinephrine and prodrug compositions |
| US11648197B2 (en) | 2018-06-28 | 2023-05-16 | Arx, Llc | Dispensing method for producing dissolvable unit dose film constructs |
| US12440472B2 (en) * | 2021-06-16 | 2025-10-14 | Intelgenx Corp. | Stable tryptamine oral films |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5879690A (en) * | 1995-09-07 | 1999-03-09 | Perricone; Nicholas V. | Topical administration of catecholamines and related compounds to subcutaneous muscle tissue using percutaneous penetration enhancers |
| US20030124176A1 (en) * | 1999-12-16 | 2003-07-03 | Tsung-Min Hsu | Transdermal and topical administration of drugs using basic permeation enhancers |
| US20060073173A1 (en) * | 2004-10-04 | 2006-04-06 | Maria Banach | Large-scale manufacturing process for the production of pharmaceutical compositions |
| US20110257096A1 (en) * | 2004-08-25 | 2011-10-20 | Aegis Therapeutics, Inc. | Compositions for drug administration |
| US20130085105A1 (en) * | 2010-03-25 | 2013-04-04 | The Provost, Fellows and Scholars of the College of Holy Trinity and Undivided Trinity of Queen Eli | Transdermal Administration Of Peptides |
| WO2015078893A1 (fr) * | 2013-11-28 | 2015-06-04 | Societe D'exploitation De Produits Pour Les Industries Chimiques Seppic | Composition d'alkyl polyglucosides et d'esters gras d'aminoacides cationisés |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8620035D0 (en) * | 1986-08-18 | 1986-10-01 | Sandoz Ltd | Organic compounds |
| GB2193891B (en) * | 1986-08-18 | 1990-07-25 | Sandoz Ltd | Nasal pharmaceutical composition containing a somatostatin anologue. |
| US7425292B2 (en) | 2001-10-12 | 2008-09-16 | Monosol Rx, Llc | Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom |
| US7666337B2 (en) | 2002-04-11 | 2010-02-23 | Monosol Rx, Llc | Polyethylene oxide-based films and drug delivery systems made therefrom |
| US8603514B2 (en) | 2002-04-11 | 2013-12-10 | Monosol Rx, Llc | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
| US7357891B2 (en) | 2001-10-12 | 2008-04-15 | Monosol Rx, Llc | Process for making an ingestible film |
| US8765167B2 (en) | 2001-10-12 | 2014-07-01 | Monosol Rx, Llc | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
| SE0302924D0 (sv) * | 2003-11-05 | 2003-11-05 | Camurus Ab | Pharmaceutical composition having a cationic excipient |
| ZA200711040B (en) * | 2005-06-03 | 2009-04-29 | Acrux Dds Pty Ltd | Method and composition for transdermal drug delivery |
| WO2011071860A2 (en) | 2009-12-07 | 2011-06-16 | Alnylam Pharmaceuticals, Inc. | Compositions for nucleic acid delivery |
| GB2478849A (en) * | 2010-03-16 | 2011-09-21 | Chiasma Inc | Improved pharmecutical compositions and methods of delivery |
| WO2012070028A1 (en) * | 2010-11-26 | 2012-05-31 | University Of The Witwatersrand, Johannesburg | A pharmaceutical dosage form |
| KR20150027831A (ko) * | 2012-07-06 | 2015-03-12 | 레오 파마 에이/에스 | 피부에 활성 성분을 전달하기 위한 막-형성 중합체를 포함하는 국소 조성물 |
| US20170119660A1 (en) * | 2015-10-29 | 2017-05-04 | Solubest Ltd | Pharmaceutical compositions for transmucosal delivery |
-
2018
- 2018-09-26 EP EP18786579.5A patent/EP3687508A1/en active Pending
- 2018-09-26 CN CN201880062678.9A patent/CN111148512A/zh active Pending
- 2018-09-26 JP JP2020538776A patent/JP2020535232A/ja active Pending
- 2018-09-26 CA CA3076751A patent/CA3076751A1/en active Pending
- 2018-09-26 IL IL273477A patent/IL273477B2/en unknown
- 2018-09-26 BR BR112020005875-0A patent/BR112020005875A2/pt unknown
- 2018-09-26 IL IL311142A patent/IL311142A/en unknown
- 2018-09-26 WO PCT/US2018/052927 patent/WO2019067596A1/en not_active Ceased
- 2018-09-26 KR KR1020207011909A patent/KR20200059269A/ko active Pending
- 2018-09-26 US US16/143,036 patent/US20190091281A1/en active Pending
-
2024
- 2024-07-05 JP JP2024108581A patent/JP2024156672A/ja active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5879690A (en) * | 1995-09-07 | 1999-03-09 | Perricone; Nicholas V. | Topical administration of catecholamines and related compounds to subcutaneous muscle tissue using percutaneous penetration enhancers |
| US20030124176A1 (en) * | 1999-12-16 | 2003-07-03 | Tsung-Min Hsu | Transdermal and topical administration of drugs using basic permeation enhancers |
| US20110257096A1 (en) * | 2004-08-25 | 2011-10-20 | Aegis Therapeutics, Inc. | Compositions for drug administration |
| US20060073173A1 (en) * | 2004-10-04 | 2006-04-06 | Maria Banach | Large-scale manufacturing process for the production of pharmaceutical compositions |
| US20130085105A1 (en) * | 2010-03-25 | 2013-04-04 | The Provost, Fellows and Scholars of the College of Holy Trinity and Undivided Trinity of Queen Eli | Transdermal Administration Of Peptides |
| WO2015078893A1 (fr) * | 2013-11-28 | 2015-06-04 | Societe D'exploitation De Produits Pour Les Industries Chimiques Seppic | Composition d'alkyl polyglucosides et d'esters gras d'aminoacides cationisés |
Non-Patent Citations (2)
| Title |
|---|
| GREGOR WOLANY:, ZUR BUKKALEN APPLIKATION UND ABSORPTION DES OKTAPEPTIDS OCTREOTID;, 1 January 1990 (1990-01-01) * |
| MERKLE H P ET AL:, BUCCAL DELIVERY FOR PEPTIDE DRUGS, 1 July 1992 (1992-07-01) * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024156672A (ja) | 2024-11-06 |
| IL273477B1 (en) | 2024-04-01 |
| BR112020005875A2 (pt) | 2020-09-29 |
| CA3076751A1 (en) | 2019-04-04 |
| EP3687508A1 (en) | 2020-08-05 |
| KR20200059269A (ko) | 2020-05-28 |
| JP2020535232A (ja) | 2020-12-03 |
| IL273477A (en) | 2020-05-31 |
| US20190091281A1 (en) | 2019-03-28 |
| CN111148512A (zh) | 2020-05-12 |
| WO2019067596A1 (en) | 2019-04-04 |
| IL311142A (en) | 2024-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273477B2 (en) | Delivery pharmaceutical compositions including permeation enhancers | |
| DK180339B1 (en) | Nicotine pouch composition and pouch comprising such | |
| Morales et al. | Novel strategies for the buccal delivery of macromolecules | |
| US20230181497A1 (en) | Ketorolac tromethamine compositions for treating or preventing ocular pain | |
| US20060074025A1 (en) | Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability | |
| JP3567103B2 (ja) | ヘッジホッグ蛋白質の薬学的組成物およびその使用 | |
| EP1951198B1 (en) | Intranasal administration of rapid acting insulin | |
| US20080318837A1 (en) | Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide | |
| US20080234200A1 (en) | Method of treatment of a metabolic disease using intranasal administration of exendin peptide | |
| WO1989002279A1 (en) | Trans-mucosal delivery formulations and a method for preparation thereof | |
| BR9708078A (pt) | Produtos farmaceuticos de peptídeo orais | |
| EP1959987A2 (en) | Mucosal delivery of stabilized formulations of exendin | |
| Dodla et al. | Buccal penetration enhancers-an overview | |
| WO2007146448A1 (en) | Pharmaceutical formulations of glp-1 derivatives | |
| EP1965828A2 (en) | Pharmaceutical formulation for increased epithelial permeability of glucose-regulating peptide | |
| US20110135752A1 (en) | Methods For Preserving Ophthalmic Solutions and Preserved Ophthalmic Solutions | |
| JP2020535232A5 (https=) | ||
| CN1671347A (zh) | 酶增强的气味清新薄膜 | |
| WO2007061434A2 (en) | A pharmaceutical formulation of glp-1 and its use for treating a metabolic syndrome | |
| US20070140897A1 (en) | Ph stable biguanide composition and method of treatment and prevention of infections | |
| US20040214797A1 (en) | Preserved pharmaceutical compositions comprising cyclodextrins | |
| US20070185035A1 (en) | Enhanced mucosal administration of neuroprotective peptides | |
| JP2005179242A (ja) | 眼科用組成物 | |
| JPH11130645A (ja) | 歯周疾患治療用シート | |
| JPWO1998030221A1 (ja) | 点眼用ジフルプレドナート含有ｏ／ｗエマルジョン組成物 |